From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
CP
N= 90
CLD
N = 87
Antibiotics
9 (10)
14 (16)
Granulocyte colony-stimulating factor
41 (46)
45 (52)
RBC transfusion â€
3 (3)
12 (14)
Platelet transfusion
0 (0)
Hospitalization
11 (12)
13 (15)